Artwork

Innhold levert av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Revolutionizing Autoimmune Medicine: MyMD Pharmaceuticals Innovative Therapies

41:49
 
Del
 

Manage episode 379814879 series 1551347
Innhold levert av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Are you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

  continue reading

154 episoder

Artwork
iconDel
 
Manage episode 379814879 series 1551347
Innhold levert av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI). Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av BioHealth Innovation, Inc. (BHI), BioHealth Innovation, and Inc. (BHI) eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

Are you interested in exploring cutting-edge autoimmune medicines? In this episode of BioTalk with Rich Bendis, we're delving deep into the world of transformative therapies with two remarkable guests, Dr. Chris Chapman and Dr. Adam Kaplin, from MyMD Pharmaceuticals. MyMD Pharmaceuticals is on a mission to make that a reality. Their lead clinical candidate, MYMD-1®, has the potential to reshape the entire field. But how does MYMD-1 work, and what sets it apart from current treatments? Join us as we unravel the science behind this revolutionary therapy and explore the potential indications and patient populations it could benefit. And that's not all. We also spotlight Supera-CBD, a novel synthetic cannabidiol with incredible potency and anti-inflammatory effects. How could this innovation change the landscape of chronic pain and anxiety management? Don't miss this episode of BioTalk with Rich Bendis as we embark on a journey into the future of autoimmune medicine with MyMD Pharmaceuticals. Tune in now and be part of the conversation.

  continue reading

154 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett